| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6095231 | Gastroenterology | 2014 | 45 Pages |
Abstract
Once-daily MK-5172 (100 mg) with PR for 24 or 48 weeks was highly effective and well tolerated among treatment-naive patients with HCV genotype 1 infection without cirrhosis. Studies are underway to evaluate interferon-free MK-5172-based regimens. ClinicalTrials.gov number: NCT01353911.
Keywords
ADMEchronic HCVresistance-associated variantRAVBOCcEVRSVR24Mrp2ALTNS3/4AASTAspartate aminotransferaseAlanine aminotransferaseBoceprevirabsorption, distribution, metabolism, and excretionResponse-guided therapyProtease inhibitorHepatitis C virusHCVSustained virologic responsemultidrug resistance-associated protein 2genotype 1complete early virologic response
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Michael P. Manns, John M. Vierling, Bruce R. Bacon, Savino Bruno, Oren Shibolet, Yaacov Baruch, Patrick Marcellin, Luzelena Caro, Anita Y.M. Howe, Christine Fandozzi, Jacqueline Gress, Christopher L. Gilbert, Peter M. Shaw, Michael P. Cooreman,